208 related articles for article (PubMed ID: 28110521)
1. From Cells to Mice to Target: Characterization of NEU-1053 (SB-443342) and Its Analogues for Treatment of Human African Trypanosomiasis.
Devine WG; Diaz-Gonzalez R; Ceballos-Perez G; Rojas D; Satoh T; Tear W; Ranade RM; Barros-Álvarez X; Hol WG; Buckner FS; Navarro M; Pollastri MP
ACS Infect Dis; 2017 Mar; 3(3):225-236. PubMed ID: 28110521
[TBL] [Abstract][Full Text] [Related]
2. Hit-to-Lead Optimization of Benzoxazepinoindazoles As Human African Trypanosomiasis Therapeutics.
Klug DM; Tschiegg L; Diaz R; Rojas-Barros D; Perez-Moreno G; Ceballos G; García-Hernández R; Martinez-Martinez MS; Manzano P; Ruiz LM; Caffrey CR; Gamarro F; Pacanowska DG; Ferrins L; Navarro M; Pollastri MP
J Med Chem; 2020 Mar; 63(5):2527-2546. PubMed ID: 31670951
[TBL] [Abstract][Full Text] [Related]
3. Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.
Woodring JL; Bachovchin KA; Brady KG; Gallerstein MF; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Pollastri MP
Eur J Med Chem; 2017 Dec; 141():446-459. PubMed ID: 29049963
[TBL] [Abstract][Full Text] [Related]
4. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
Ferrins L; Rahmani R; Sykes ML; Jones AJ; Avery VM; Teston E; Almohaywi B; Yin J; Smith J; Hyland C; White KL; Ryan E; Campbell M; Charman SA; Kaiser M; Baell JB
Eur J Med Chem; 2013 Aug; 66():450-65. PubMed ID: 23831695
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.
Ferrigno F; Biancofiore I; Malancona S; Ponzi S; Paonessa G; Graziani R; Bresciani A; Gennari N; Di Marco A; Kaiser M; Summa V; Harper S; Ontoria JM
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3689-3692. PubMed ID: 30482621
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei.
Cleghorn LA; Albrecht S; Stojanovski L; Simeons FR; Norval S; Kime R; Collie IT; De Rycker M; Campbell L; Hallyburton I; Frearson JA; Wyatt PG; Read KD; Gilbert IH
J Med Chem; 2015 Oct; 58(19):7695-706. PubMed ID: 26418485
[TBL] [Abstract][Full Text] [Related]
7. Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei.
Faria J; Moraes CB; Song R; Pascoalino BS; Lee N; Siqueira-Neto JL; Cruz DJ; Parkinson T; Ioset JR; Cordeiro-da-Silva A; Freitas-Junior LH
J Biomol Screen; 2015 Jan; 20(1):70-81. PubMed ID: 25342146
[TBL] [Abstract][Full Text] [Related]
8. Functional and structural analysis of AT-specific minor groove binders that disrupt DNA-protein interactions and cause disintegration of the Trypanosoma brucei kinetoplast.
Millan CR; Acosta-Reyes FJ; Lagartera L; Ebiloma GU; Lemgruber L; Nué Martínez JJ; Saperas N; Dardonville C; de Koning HP; Campos JL
Nucleic Acids Res; 2017 Aug; 45(14):8378-8391. PubMed ID: 28637278
[TBL] [Abstract][Full Text] [Related]
9. Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening.
Pedró-Rosa L; Buckner FS; Ranade RM; Eberhart C; Madoux F; Gillespie JR; Koh CY; Brown S; Lohse J; Verlinde CL; Fan E; Bannister T; Scampavia L; Hol WG; Spicer T; Hodder P
J Biomol Screen; 2015 Jan; 20(1):122-30. PubMed ID: 25163684
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of synthetic cordycepin analogues as experimental therapeutics for African trypanosomiasis.
Vodnala SK; Lundbäck T; Yeheskieli E; Sjöberg B; Gustavsson AL; Svensson R; Olivera GC; Eze AA; de Koning HP; Hammarström LG; Rottenberg ME
J Med Chem; 2013 Dec; 56(24):9861-73. PubMed ID: 24283924
[TBL] [Abstract][Full Text] [Related]
11. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.
Valenciano AL; Ramsey AC; Santos WL; Mackey ZB
Bioorg Med Chem; 2016 Oct; 24(19):4647-4651. PubMed ID: 27519462
[TBL] [Abstract][Full Text] [Related]
12. Optimization of 2-(1H-imidazo-2-yl)piperazines series of Trypanosoma brucei growth inhibitors as potential treatment for the second stage of HAT.
Ciammaichella A; Ferrigno F; Basta A; D'Amico M; Biancofiore I; Nardi V; Ponzi S; Graziani R; Gennari N; Vittoria Orsale M; Fini I; Paonessa G; Summa V; Harper S; Ontoria JM
Bioorg Med Chem Lett; 2020 Jun; 30(12):127207. PubMed ID: 32354566
[TBL] [Abstract][Full Text] [Related]
13. Identification of Trypanosoma brucei AdoMetDC Inhibitors Using a High-Throughput Mass Spectrometry-Based Assay.
Volkov OA; Cosner CC; Brockway AJ; Kramer M; Booker M; Zhong S; Ketcherside A; Wei S; Longgood J; McCoy M; Richardson TE; Wring SA; Peel M; Klinger JD; Posner BA; De Brabander JK; Phillips MA
ACS Infect Dis; 2017 Jul; 3(7):512-526. PubMed ID: 28350440
[TBL] [Abstract][Full Text] [Related]
14. In vitro Anti-Trypanosomal Activities of Indanone-Based Chalcones.
Beteck RM; Legoabe LJ; Isaacs M; Hoppe HC
Drug Res (Stuttg); 2019 Jun; 69(6):337-341. PubMed ID: 30452077
[TBL] [Abstract][Full Text] [Related]
15. In Vitro and In Vivo Investigation of the Inhibition of Trypanosoma brucei Cell Growth by Lipophilic Bisphosphonates.
Yang G; Zhu W; Kim K; Byun SY; Choi G; Wang K; Cha JS; Cho HS; Oldfield E; No JH
Antimicrob Agents Chemother; 2015 Dec; 59(12):7530-9. PubMed ID: 26392508
[TBL] [Abstract][Full Text] [Related]
16. Hit-to-lead development of the chamigrane endoperoxide merulin A for the treatment of African sleeping sickness.
Navarro G; Chokpaiboon S; De Muylder G; Bray WM; Nisam SC; McKerrow JH; Pudhom K; Linington RG
PLoS One; 2012; 7(9):e46172. PubMed ID: 23029428
[TBL] [Abstract][Full Text] [Related]
17. Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis.
Klug DM; Mavrogiannaki EM; Forbes KC; Silva L; Diaz-Gonzalez R; Pérez-Moreno G; Ceballos-Pérez G; Garcia-Hernández R; Bosch-Navarrete C; Cordón-Obras C; Gómez-Liñán C; Saura A; Momper JD; Martinez-Martinez MS; Manzano P; Syed A; El-Sakkary N; Caffrey CR; Gamarro F; Ruiz-Perez LM; Gonzalez Pacanowska D; Ferrins L; Navarro M; Pollastri MP
J Med Chem; 2021 Jul; 64(13):9404-9430. PubMed ID: 34156862
[TBL] [Abstract][Full Text] [Related]
18. Novel pyrrolobenzoxaboroles: design, synthesis, and biological evaluation against Trypanosoma brucei.
Wu P; Zhang J; Meng Q; Nare B; Jacobs RT; Zhou H
Eur J Med Chem; 2014 Jun; 81():59-75. PubMed ID: 24826816
[TBL] [Abstract][Full Text] [Related]
19. Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors.
Bayliss T; Robinson DA; Smith VC; Brand S; McElroy SP; Torrie LS; Mpamhanga C; Norval S; Stojanovski L; Brenk R; Frearson JA; Read KD; Gilbert IH; Wyatt PG
J Med Chem; 2017 Dec; 60(23):9790-9806. PubMed ID: 29125744
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluoroimidazo[4,5-b]pyridine Is a Privileged Fragment That Conveys Bioavailability to Potent Trypanosomal Methionyl-tRNA Synthetase Inhibitors.
Zhang Z; Koh CY; Ranade RM; Shibata S; Gillespie JR; Hulverson MA; Huang W; Nguyen J; Pendem N; Gelb MH; Verlinde CL; Hol WG; Buckner FS; Fan E
ACS Infect Dis; 2016 Jun; 2(6):399-404. PubMed ID: 27627628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
